HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Schnittger Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

1/2016Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
1/2016Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
4/2014The role of different genetic subtypes of CEBPA mutated AML.
7/2011Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.
4/2011Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
8/2009New insights to the MLL recombinome of acute leukemias.
6/2007The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
11/2005Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
4/2005[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
1/2004Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Schnittger Research Topics

Disease

13Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2016 - 02/2001
6BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2016 - 02/2003
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/2020 - 02/2001
5Chromosome Aberrations (Chromosome Abnormalities)
12/2014 - 02/2003
4Neoplasms (Cancer)
01/2017 - 08/2008
4Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2016 - 06/2004
3Residual Neoplasm
07/2020 - 08/2008
3Leukemia
08/2009 - 07/2000
2Thrombocytosis (Thrombocythemia)
06/2014 - 09/2013
2Blast Crisis (Blast Phase)
03/2013 - 02/2001
1BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)
09/2013
1Multiple Myeloma
08/2012
1Philadelphia Chromosome
03/2010
1Acute Promyelocytic Leukemia
12/2009
1Hematologic Neoplasms (Hematological Malignancy)
06/2007
1Eosinophilia
06/2007
1Refractory Anemia
06/2004
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
06/2004
1Acute Biphenotypic Leukemia (Leukemia, Mixed Cell)
02/2001
1Myeloid Leukemia (Leukemia, Myelocytic)
05/2000

Drug/Important Bio-Agent (IBA)

4DNA (Deoxyribonucleic Acid)IBA
01/2017 - 05/2006
4Tyrosine Kinase InhibitorsIBA
03/2016 - 06/2007
3Imatinib Mesylate (Gleevec)FDA Link
10/2014 - 02/2003
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2020 - 01/2019
1ChromatinIBA
01/2017
1Transcription Factors (Transcription Factor)IBA
01/2017
1S 0139 (97-139)IBA
07/2014
1CalreticulinIBA
06/2014
1CCAAT-Enhancer-Binding ProteinsIBA
04/2014
1RNA Splicing FactorsIBA
09/2013
1Janus Kinase 2IBA
09/2013
1Carrier Proteins (Binding Protein)IBA
09/2013
1Dasatinib (BMS 354825)FDA Link
03/2013
1NucleotidesIBA
03/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2012
1Complementary DNA (cDNA)IBA
07/2011
1NucleophosminIBA
04/2011
1Tretinoin (Retinoic Acid)FDA LinkGeneric
12/2009
1Cytarabine (Cytosar-U)FDA LinkGeneric
12/2009
1tocophersolanIBA
08/2009
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2005
1Paclitaxel (Taxol)FDA LinkGeneric
06/2004
1Etoposide (VP 16)FDA LinkGeneric
06/2004
1Cisplatin (Platino)FDA LinkGeneric
06/2004
1IfosfamideFDA LinkGeneric
06/2004
1CCAAT-Enhancer-Binding Protein-alphaIBA
03/2001
1AntigensIBA
02/2001
1Monoclonal AntibodiesIBA
07/2000
1Chondroitin Sulfate ProteoglycansIBA
07/2000

Therapy/Procedure

11Therapeutics
02/2016 - 05/2000
2Stem Cell Transplantation
03/2016 - 12/2004
1Drug Therapy (Chemotherapy)
01/2016
1Induction Chemotherapy
12/2009
1Transplantation
08/2008